Adult Dosing
Pharyngitis/Tonsillitis
Acute bacterial maxillary sinusitis
Acute bacterial exacerbations of chronic bronchitis
- 250-500 mg PO bid for atleast 10 days
Secondary bacterial infections of acute bronchitis
- 250-500 mg PO bid x 5-10 days
Uncomplicated skin and skin structure infections
- 250-500 mg PO bid x 10 days
Uncomplicated urinary tract infections
- 250 mg PO bid x 7-10 days
Uncomplicated gonorrhea
Lyme disease
Uncomplicated gonoccocal infections
- Adolescents: 1000 mg PO x 1
Pediatric Dosing
Mild to moderate bacterial infections (acute otitis media, acute bacterial maxillary sinusitis, impetigo)
- 3 months-12 yrs: 30 mg/kg/day suspension PO divided bid x 10 days. Max: 1000 mg/day
- >12 yrs: 250-500 tablet PO bid x 5-10 days
Pharyngitis/Tonsillitis
- 3 months-12 yrs: 20 mg/kg/day suspension PO divided bid x 10 days. Max: 500 mg/day
- > 12 yrs: 250 mg tablet PO bid x 10 days
[Outline]
Renal Dose Adjustment (Based on CrCl)
- Renal impairment: Dose adjustments not defined
Hepatic Dose Adjustment
- Hepatic impairment: Dose adjustments not defined
- Cefuroxime tablets and oral suspension are not bioequivalent and are not substitutable on a mg/mg basis
- Before starting therapy with cefuroxime, carefully inquire if patients have had previous hypersensitivity to cefuroxime, other cephalosporins, penicillins or other b-lactams. Extreme caution must be exercised as cross reactivity among beta-lactam antibiotics is clearly documented and may occur in up to 10% of patients
- If an allergic reaction occurs, discontinue use and institute appropriate therapeutic measures
- Serious hypersensitivity reactions may require therapy with epinephrine and other emergency measures including oxygen, IV fluids, IV antihistamines, corticosteroids, pressor amines and airway management
- Cephalosporins may be associated with a fall in prothrombin activity.Prothrombin time should be monitored in patients at risk (renal/hepatic impairment, poor nutritional state, anticoagulant therapy) and exogenous Vitamin K administered as indicated
- Cefuroxime should be used to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Prescribing in the absence of a proven or strongly suspected bacterial infection increases the risk of the development of drug-resistant bacteria
- Obtain culture and susceptibility studies before starting therapy to determine the susceptibility of the causative organisms to cefoxitin
- Clostridium difficile associated diarrhea which may vary in severity from mild to fatal colitis, has been reported with use of cephalosporins
- Prolonged use may result in the overgrowth of nonsusceptible organisms
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Concurrent potent diuretics
- Hypersensitivity to penicillins
- Patients on anticoagulant therapy
- Hx of GI malabsorption esp colitis
- Seizure disorder
- Malnutrition
Pregnancy Category:B
Breastfeeding: This drug is considered safe and compatible with breastfeeding based upon data from LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 19 May 2010). Occasionally disruption of the infant's gastrointestinal flora has been reported with the use of cephalosporins. Manufacturer advises caution.
Pricing data from www.DrugStore.com in U.S.A.
- Ceftin 250 MG TABS [Bottle] (GLAXO SMITH KLINE)
20 mg = $213.98
60 mg = $601.95 - Ceftin 500 MG TABS [Bottle] (GLAXO SMITH KLINE)
20 mg = $359.97
60 mg = $1049.98
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
